p53 and RB expression predict progression in T1 bladder cancer

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 829-834

  Grossman, H Barton ^a   Liebert, Monica ^a   Antelo, Miguel ^a   Dinney, Colin P N ^a   Hu, Shi Xue ^a   Palmer, J Lynn ^a   Benedict, William F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0031953814     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Herr, H. W., Laudone, V. P., Badalament, R. A., Oettgen, H. F., Sogani, P. C., Freedman, B. D., Melamed, M. R., and Whitmore, W. F. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol., 6: 1450-1455, 1988.
2. Cookson, M. S., and Sarosdy, M. F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J. Urol., 146: 797-801, 1992.
3. Eure, G. R., Cundiff, M. R., and Schelhammer, P. F. Bacillus Calmette-Guérin therapy for high risk stage T1 superficial bladder cancer. J. Urol., 147: 376-379, 1992.
4. Serretta, V., Piazza, S., Pavone, C., Piazza, B., and Pavone-Macaluso, M. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder. Urology, 47: 647-651, 1996.
5. Herr, H. W., Badalament, R. A., Amato, D. A., Laudone, V. P., Fair, W. R., and Whitmore, W. F. Superficial bladder cancer treated with bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression. J. Urol., 141: 22-28, 1989.
6. Hurle, R., Losa, A., Ranieri, A., Graziotti, P., and Lembo, A. Low dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J. Urol., 156: 1602-1605, 1996.
7. Heney, N. M., Ahmed, S., Flanagan, M. J., Frable, W., Corder, M. P., Jagermann, M. D., Hawkins, I. R., and the National Bladder Cancer Cooperative Group A. Superficial bladder cancer: progression and recurrence. J. Urol., 130: 1083-1086, 1983.
8. Abel, P. D., Hall, R. R., and William, G. Should pT1 transitional cell cancer of the bladder still be classified as superficial? Br. J. Urol., 62: 235-239, 1988.
9. Anderstrom, C., Johansson, S., and Nilsson, S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors. J. Urol., 124: 23-26, 1980.
10. Zhang, G. K., Uke, E. T., Sharer, W. C., Borkon, W. D., and Berstein, S. M. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J. Urol., 155: 1907-1909, 1966.
11. Holmang, S., Hedelin, H., Anderstrom, C., and Johansson, S. L. The relationship among multiple recurrences, progression and prognosis of patients with stage Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol., 153: 1823-1827, 1995.
12. Malkowicz, S. B., Nichols, P., Lieskovsky, G., Boyd, S. D., Huffman, J., and Skinner, D. G. The role of radical cystectomy in the management of high grade superficial bladder cancer (Pa, P1, Pis and P2). J. Urol., 144: 641-645, 1990.
13. Amling, C. L., Thrasher, J. B., Frazier, H. A., Dodge, R. K., Robertson, J. E., and Paulson, D. F. Radical cystectomy for stages Ta, Tis, and T1 transitional cell carcinoma of the bladder. J. Urol., 151: 31-35, 1994.
14. Sarkis, A., Dalbagni, G., Cordon-Cardo, C, Sheinfeld, J., Herr, H., Zhang, Z-F., Fair, W. R., and Reuter, V. E. Detection of p53 mutations in superficial (T1) bladder carcinomas as a marker of disease progression. J. Natl. Cancer Inst., 85: 53-59, 1993.
15. Lipponen, P. K. Over-expresssion of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int. J. Cancer, 53: 365-370, 1993.
16. Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang, Z-F., Schultz, P. K., Cordon-Cardo, C., and Scher, H. I. The prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant M-VAC. J. Clin. Oncol., 13: 1384-1390, 1995.
17. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S-C., Nichols, P. W., Skinner, D. G., Jones, P. A., and Cote, R. J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259-1264, 1994.
18. Cordon-Cardo, C., Wartinger, D., Petrylak, D., Dalbagni, G., Fair, W. R., Fuks, Z., and Reuter, V. E. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Cancer Inst., 84: 1251-1256, 1992.
19. Logothetis, C. J., Xu, H-J., Ro, J. Y., Hu, S-X., Sahin, A., Ordonez, N., and Benedict, W. F. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J. Natl. Cancer Inst., 84: 1256-1261, 1992.
20. Lipponen, P. K., and Liukkonen, T. J. O. Reduced expression of retinoblastoma (RB) gene proteins is related to cell proliferation and prognosis in transition-cell bladder cancer. J. Cancer Res. Clin. Oncol., 121: 44-50, 1995.
21. Lacombe, L., Dalbagni, G., Zhang, Z-F., Cordon-Cardo, C., Fair, W. R., Herr, H. W., and Reuter, V. E. Overexpression of p53 protein in a high risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation with clinical outcome. J. Clin. Oncol., 14: 2646-2652, 1996.
22. Cordon-Cardo, C., Zhang, Z-F., Dalbagni, G., Drobnjak, M., Charytonowicz, E., Hu, S-X., Xu, H-J., Reuter, V. E., and Benedict, W. F. Cooperative effects of p53 and RB alterations in primary superficial bladder cancer. Cancer Res., 57: 1217-1221, 1997.
23. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumor suppressor gene. Nature (Lond.), 351: 453-456, 1991.
24. Levine, A. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
25. Bataskis, J. G., and El-Naggar, A. K. p53 fifteen years after discovery. Adv. Anat. Pathol., 2: 71-88, 1995.
26. Cordon-Cardo, C., Dalbagni, D., Saez, G., Olica, M., Zhang, Z-F., Rosai, J., Reuter, V. E., and Pellicer, A. TP53 mutations in human bladder cancer: genotypic versus phenotype patterns. Int. J. Cancer, 56: 347-353, 1994.
27. Esrig, D., Spruck, C. H., III, Nichols, P., Chaiwun, B., and Cote, R. p53 nuclear protein accumulation correlates with mutation in the p53 gene, tumor grade and stage in bladder cancer. Am. J. Pathol., 143: 1389-1396, 1993.
28. Xu, H-J. Altered retinoblastoma (RB) protein expressíon ín human malignancies. Adv. Anat. Pathol., 2: 213-226, 1995.
29. Krek, W., Livingston, D. M., and Shirodkar, S. Binding to DNA, and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science (Washington DC), 262: 1557-1560, 1993.
30. Cordon-Cardo, C. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol., 147: 545-560, 1995.
31. Zhang, X., Xu, H-J., Murakami, Y., Sachse, R., Yashima, K., Hirohashi, S., Hu, S-X., Benedict, W. F., and Sekiya, T. Deletions of chromosome 13q mutations in retinoblastoma 1 and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res., 54: 4177-4182, 1994.
32. Dunn, M. D., Stein, J. P., Shi, S-R., Dickenson, M., Taylor, C., Skinner, D. G., Cote, R. J., Xu, H-J., and Benedict, W. F. Retinoblastoma protein in bladder cancer: level of expression correlates with tumor progression. J. Urol., 157: 341A, 1997.
33. Cote, R. J., Dunn, M. D., Chatterjee, S. J., Stein, J. P., Shi, S-R., Tran, Q-C., Hu, S. X., Xu, H. J., Groshen, S., Taylor, C. R., Skinner, D. G., and Benedict, W. F. Elevated and absent pRb expression is associated with bladder cancer progression, and has cooperative effects with p53. Cancer Res., 58: 1090-1094, 1998.
34. Thomas, D. J., Robinson, M. C., Charlton, R., Wilkinson, S., Shenton, B. K., and Neal, D. E. p53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br. J. Urol., 73: 533-537, 1993.
35. Soini, Y., Turpeenniemi-Hujanen, T., Kamel, D., Autio-Harmainen, H., Risteli, J., Risteli, L., Nuorva, K., Paakko, P., and Vahakangas, K. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the bladder correlates with disease progression. Br. J. Cancer, 68: 1029-1035, 1993.
36. Kornblau, S. M., Xu, H-J., Zhang, W., Hu, S-X., Beran, M., Smith, T. L., Hester, J., Estey, E., Benedict, W. F., and Deisseroth, A. B. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 84: 256-261, 1994.
37. Ludesmeyers, J. H., Subler, M. A., Shivakumar, C. V., Munoz, R. M., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P., and Deb, S. Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol., 16: 6009-6019, 1996.
38. Grossfeld, G. D., Ginsberg, D. A., Stein, J. P., Brocher, B. H., Esrig, D., Groshen, S., Dunn, M., Nichols, P. W., Taylor, C. R., Skinner, D. G., and Cote, R. J. Thrombospondin-1 expression in bladder cancer-association with p53 alterations, tumor angiogenesis, and tumor progression. J. Natl. Cancer Inst., 89: 219-227, 1997.
39. Li, J., Hu, S-X., Perng, G-S., Zhou, Y., Xu, K., Zhang, C., Seigne, J., Benedict, W. F., and Xu, H-J. Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. Oncogene, 13: 2379-2386, 1996.
40. Ovesen, H., Horn, T., and Steven, K. Long-term efficacy of intravesical bacillus Calmette-Guérin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol., 157: 1655-1659, 1997.
41. Ick, K., Schultz, M., Stout, P., and Fan, K. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. Urology, 49: 541-547, 1997.
42. Dinney, C. P. N., Parker, C., Dong, Z., Fan, D., Eve, B. Y., Bucana, C., and Radinsky, R. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin. Cancer Res., 3: 161-168, 1997.
43. Dinney, C. P. N., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998.